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Abstract 
Background: Health utilities (HU) assign preference weights to specific health states and are 
required for cost-effectiveness analyses. Existing HU for stroke inadequately reflect the 
spectrum of post-stroke disability. Using international stroke trial data, we calculated HU 
stratified by disability to improve precision in future cost-effectiveness analyses.  
Materials & Methods: We used European Quality of Life Score (EQ-5D-3L) data from the 
Virtual International Stroke Trials Archive (VISTA) to calculate HU, stratified by modified 
Rankin Scale scores (mRS) at 3 months. We applied published value sets to generate HU, and 
validated these using Ordinary Least Squares (OLS) regression, adjusting for age and baseline 
National Institutes of Health Stroke Scale (NIHSS) scores. 
Results: We included 3,858 patients with acute ischemic stroke in our analysis (mean age: 
67.5±12.5, baseline NIHSS: 12±5). We derived HU using value sets from 13 countries and 
observed significant international variation in HU distributions (Wilcoxon Signed-Rank Test 
p<0.0001, compared with UK values). For mRS=0, mean HU ranged from 0.88 to 0.95; for 
mRS=5, mean HU ranged from -0.48 to 0.22. OLS regression generated comparable HU (for 
mRS=0, HU ranged from 0.9 to 0.95; for mRS=5, HU ranged from -0.33 to 0.15). Patients’ 
mRS scores at 3 months accounted for 65-71% of variation in the generated HU.  
Conclusion: We have generated HU stratified by dependency level, using a common trial 
endpoint, and describing expected variability when applying diverse value sets to an 
international population. These will improve future cost-effectiveness analyses. However, care 
should be taken to select appropriate value sets. 
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Introduction 
Changing population demographics will increase stroke prevalence and healthcare 
burden1. With technological advances such as mechanical thrombectomy, and finite healthcare 
budgets, it is increasingly important to consider not just efficacy of new interventions but also 
the cost-effectiveness2. 
Cost-effectiveness analyses are often based on the number of quality-adjusted life years 
(QALYs) that are gained from implementing a treatment. QALYs conveniently provide a 
combined estimate of both length and quality of life and can be used across a broad range of 
conditions, treatments and settings. Calculation of QALYs is dependent on (a) reliable 
measurements of patients’ health related quality of life on at least two occasions and (b) the 
availability of accurate health utility (HU) estimates, which define and assign preference 
weights to each possible health state. HU are represented on a scale of <0 to 1, with 0 indicating 
equivalence with death, 1 representing perfect health, and negative values indicating states 
considered worse than death.  
HU can be derived using diverse health state measures, (for example the European 
Quality of Life Scale [EQ-5D-3L], the Health Utilities Index [HUI]3and the Assessment of 
Quality of Life [AQoL]4); by various elicitation methods (Standard Gamble, Time Trade Off 
[TTO] and Visual Analogue Scale [VAS]5); and from various elicitation sources or 
populations. Value sets are usually collected from the general population. They exist for a range 
of different countries and describe preference weights for a particular health state.  
For studies such as decision modelling that rely on existing sources of HU and include 
stroke as a possible health state, accurate HU must be generated6. Currently for stroke, variation 
exists in the choice of elicitation method, and the generated HU show diversity within stroke 
as a condition2. Stroke is characterised by a spectrum of functional outcomes; it is unfortunate 
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that some calculated stroke HU have described only limited functional outcome states6. 
Existing studies have described population characteristics for patients with HU <07, have 
described methods to translate functional states into EQ-5D-3L utility values8, have examined 
diversity in quality of life responses from participants from various countries, and have 
examined proxy respondents compared with self-reported outcomes9. For international stroke 
trials, HU estimates derived from a single country may not be applicable to all available trial 
data. There are limited international data to describe the range of expected HU across all 
possible levels of function, generated using a range of value sets. We sought to better inform 
future cost-effectiveness analyses that require HU estimates for stroke, by generating 
international HU based on European Quality of Life Scale (EQ-5D-3L) scores at a common 
acute stroke trial endpoint (3 months following stroke), and mapped across a spectrum of 
functional outcomes, assessed using the modified Rankin Scale (mRS).  
Methods 
Data: We conducted retrospective analyses of pooled, anonymised, patient-level data from the 
Virtual International Stroke Trials Archive (VISTA)10 on demography, (age, sex, medical 
history), neurological impairment (National Institutes of Health Stroke Scale score [NIHSS]), 
functional outcome (mRS), Quality of Life (EQ-5D-3L) and country of enrolment. The mRS 
is a 7-point observational scale that describes level of dependency, and ranges from 0 (no 
symptoms at all) to 6 (dead). The EQ-5D-3L is a standardised measurement tool for health-
related quality of life and includes domains of mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. It can also be completed by proxy for people unable 
to complete the questionnaire themselves. 
HU Generation: We utilised published country-specific preference weights (value sets) 11-23 to 
calculate HU. Each published value set was elicited from general population samples from the 
respective countries, using the Time Trade off (TTO) method. These value sets were applied 
 6 
 
in turn to individual-level EQ-5D-3L health state descriptions based on the five domains of 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression for patients in our 
dataset (Supplement I).  
We applied each published value set to our data, stratifying by mRS score at 3 months 
to illustrate expected variation when applying any single value set to an international trial 
population, as commonly occurs in cost effectiveness analysis. We examined potential 
differences in the distributions of HU according to the value set applied, with the Wilcoxon 
Signed Rank Test, and using HU generated from the UK value set as a reference population. 
Supplementary analyses applied each published value set to the country-specific population 
from which it was derived; if populations existed where no country-specific value set was 
available, we applied the value set of the nearest neighbouring country. 
Validation: Ordinary Least Squares (OLS) regression24, 25 is recommended as a method 
of estimating unknown parameters (such as HU) from existing data (for example, mRS)26. OLS 
Regression examines error: the differences between predicted outcomes and reality, and 
attempts to fit a line through the data that minimises the sum of the squared errors. This method 
was also previously described by Rivero-Arias et al8. We used OLS Regression to generate an 
equation to estimate HU based on mRS scores from our international population. We examined 
the proportion of variation in HU that was explained by mRS, adjusting for patients’ age and 
baseline NIHSS. The National Institute for Health and Clinical Excellence (NICE) caution 
against over-fitting covariates in an OLS regression; age and NIHSS were selected due to the 
strength of their association with post-stroke outcomes in our dataset (p<0.0001).  
 For this regression analysis, we applied published value sets from the USA, UK, Spain, 
Germany, China and Poland. These value sets were selected as they were generated using the 
most robust sample sizes11, were published in the EQ-5D-3L inventory and user guide, 
represented countries that were typically included in international multicentre RCTs, and/ or 
 7 
 
represented areas where emerging stroke research datasets warranted the generation of robust 
HU estimates. Performance was assessed using goodness of fit (adjusted R-squared values). 
We described the clinical and demographic characteristics of our population to inform 
generalisability for application to other clinical stroke populations. 
Results 
We identified and extracted eligible data on 4,946 patients (mean age: 68.8±12.6 years, 
2231 (45%) female, baseline NIHSS: 12±9; Table 1) for whom assessment of EQ-5D-3L and 
mRS had been performed. Our analysis dataset comprised patients who were alive and had 
complete mRS and EQ-5D-3L scores at 3 months following stroke; by 3 months 817 (17.0%) 
patients had died; complete data on EQ-5D-3L (76.4% subject and 21.8% proxy respondents) 
and mRS were available for 3,858 patients (mean age: 67.5±12.5, baseline NIHSS: 12±5) and 
missing for 271. Thirty-six countries were represented in our analysis dataset (Supplement II).  
Age and initial stroke severity by NIHSS were largely comparable across countries 
having a sample size of more than 50 patients. Medical history and use of thrombolytics varied 
by country of enrolment particularly in those countries that enrolled fewer patients (Argentina, 
Brazil, Chile, Finland, Greece, Hong Kong, Italy, Malaysia, Mexico, Netherlands, Norway, 
South Africa, South Korea and Sweden; Supplement II).     
HU estimates: After applying each published value set to our international dataset in turn, for 
mRS=0, mean HU ranged from 0.88 to 0.95; for mRS=5, mean HU ranged from -0.48 to 0.22 
(Table 2). HU for mRS=5 were perceived as corresponding to a health state that was worse 
than death when applying value sets from Singapore (-0.48), Spain (-0.34) and the UK (-0.15). 
Similar HU ranges were observed when excluding proxy responses on EQ-5D-3L (Supplement 
III). The Wilcoxon Signed Rank Test revealed significant differences between the HU 
distributions generated using each country’s value set, when compared with those generated 
using the UK value set (p<0.0001 for each country; Table 2).  
 8 
 
Supplement IV describes HU generated by applying country-specific value sets to 
appropriate sub-populations. We observed that for mRS=0, the mean HU estimates ranged 
between 0.81 and 0.98. For mRS=5, mean HU ranged between -0.48 and 0.27.  
Validation: After applying OLS regression, mRS scores at 3 months accounted for 65-71% of 
the variation in the generated HU estimates. The HU generated using OLS regression were 
consistent with those generated by applying each value set to the analysis dataset (Table 3). 
For mRS=0 mean HU ranged between 0.9 and 0.95; for mRS=1, mean HU ranged between 
0.81 and 0.9, and for mRS=5, mean HU ranged between -0.33 and 0.15.  
Discussion 
We generated exemplar international acute stroke HU based on published value sets, 
describing case mix and stratifying by mRS at 3 months to better inform future cost-
effectiveness analyses. The range of observed HU generated by applying each published value 
set to our international population was similar to those generated when using OLS regression, 
and when excluding proxy responses.  
 For mRS of 0, the mean HU ranged between 0.88 and 0.95, indicating that even though 
these patients were by definition asymptomatic, there were extraneous influences on the 
individual that affected perception of their health state. mRS states can be assigned on the basis 
of physical disability, cognitive impairment or a combination of both. Furthermore, the EQ-
5D-3L has 5 domains and within any mRS level, patients can exhibit variation in which EQ-
5D-3L domains have been affected. Therefore, it is possible for considerable variation to exist 
in HU estimates within a single mRS level. It is also possible that scoring errors or 
inconsistencies on mRS and on EQ-5D-3L contribute to this variation. 
We observed that application of different value sets resulted in significantly different 
distributions of HU (compared with UK values). Since value sets vary according to country, 
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heterogeneity in HU is expected when these diverse value sets are applied to a single multi-
centred international trial population. The variation in value sets could arise from differing 
access to, and levels of health care services available, as well as differing cultural perceptions 
of disability across participating countries. This issue applies to both health state measurement 
and health state valuation, and should be taken into consideration when selecting appropriate 
value sets to inform cost-effectiveness of an intervention.   
Guidance is needed on the application of appropriate value sets for pooled analyses of 
international populations. The application of one value set to an international population is 
commonly practiced, often as a matter of convenience or because this approach is applied to 
the corresponding cost data. However, this approach has some limitations; between country 
differences exist in health-related QoL, costs of healthcare, the degree of social support 
available and cultural perceptions of disability. These differences are not captured when 
applying a single value set to an international population. Application of country-specific value 
sets increases the relevance of the generated HU to each country, but creates problems for 
pooling of data for analyses (which is often necessary to preserve sample size). Our 
supplementary analysis still necessitated the application of a single value set to multiple 
neighbouring countries (Supplement IV). For example, data from Germany, Switzerland, Italy, 
and Greece were analysed using the German value set. The latter countries have strong family 
support for stroke survivors, and the application of German preference weights to these 
participants may not fully capture subtle differences in health perceptions within the same mRS 
level. Similar issues arise with the application of the USA value set to Central and South 
American countries. Our application of country-specific value sets to appropriate populations 
(Supplement IV) highlights a challenge when dealing with smaller subgroups. We observed 
that when applying a Nordic value set to Nordic countries, HU were greater for mRS=2 (0.92), 
than for mRS=0 (0.9). Similarly, applying the UK value set to UK participants, HU for mRS=1 
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(0.9) was greater than HU for mRS=0 (0.81). This difference could be attributed to participant 
heterogeneity. Pooling data hides the country-level issues, and results are often not specifically 
relevant to any participating counties, while sub-group analyses carry analytical deficiencies. 
There is often a trade-off between the availability & appropriateness of value sets for use in an 
international population, and preservation of a large enough sample size on which inferences 
can be made on health perception and cost-effectiveness.  
Debate also exists over the appropriate participant population from which to derive HU 
estimates6. Those at risk of stroke are traditionally seen to be more  suited to inform decisions 
from a patient’s perspective27. However preference values derived from hypothetical scenarios 
may not be valid predictors of the preferences associated with actual experienced health 
states28; stroke survivors typically assign higher values to health states than those at risk of 
stroke, or healthy participants6. Nevertheless, preference weight estimates from the general 
population are recommended when assessing cost-effectiveness from a societal perspective6, 
27. 
We described HU generated from application of both single and country-specific value 
sets to an international population. Previous studies have utilised a single country’s value set7, 
described HU generated from a range of stroke and non-stroke populations, or stratified by 
broad categories of disability (minor stroke=mRS 2-3, major stroke=mRS 4-5)6. Previous 
estimates elicited from stroke survivors using the EQ-5D-3L described utilities of 0.71 and 
0.32 for minor and major stroke respectively6. This contrasts with our findings where we 
observed a much wider HU range for the transition from mRS 2 to 5 (from 0.83 to -0.48). 
Although our data give HU values that differ from previously published estimates, our results 
are still within a range that would seem credible based on previous work6. Furthermore, our 
generation of HU based on mapping approaches (Table 3) are consistent overall with HU 
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generated from a prior study by Rivero-Arias et al8, though it should be noted that their study 
generated HU at different time points post-stroke.  
Our approach to HU had a number of strengths. Our data are representative of the range 
of respondents that are typical in acute stroke RCTs. We employed OLS regression24 to validate 
our estimates. We used a generic patient reported outcome measure (EQ-5D-3L) that has been 
specified as a preferred method of utility measurement in clinical trials24. Our analysis includes 
a much larger and more geographically diverse patient population than examined in previous 
studies. Baseline data suggest that included patients are broadly representative of acute stroke 
trial cohorts.  
A limitation of our study is that perspectives on health states may change according to 
the time since stroke, and the values elicited based on EQ-5D-3L may not fully capture 
information from some patient subgroups such as those with communication problems. Those 
with cognitive or visual problems may rely on proxies to complete the EQ-5D-3L and thus 
their views may not be accurately represented. However, in our analysis dataset, 76.4% of EQ-
5D-3L responses were elicited from stroke survivors themselves. Additionally, we analysed 
data only from those who had complete scores on all domains of EQ-5D-3L at 3 months; this 
may have biased the sample sizes available at higher levels of dependence. Furthermore, our 
data are based on an acute stroke clinical trial population. The HU generated for each stratum 
of mRS are therefore based on the experiences of a subgroup of the general stroke population. 
Future work could examine the generalisability of the HU generated in our population to 
general stroke population, and additional work is needed to examine the minimum sample size 
required for reliable country-specific HU generation.   
Our study is based on acute stroke clinical trial data including information on 
dependency at a common endpoint, and involving patients from countries typically represented 
in acute stroke trials. Our findings can inform cost-effectiveness analyses of interventions in 
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the acute stroke setting by providing conservative estimates of HU across a range of 
dependency levels; this may be of particular use to study designs reliant on secondary data 
sources e.g. decision models. HU could feasibly be calculated in future studies through the 
collection of EQ-5D-3L data in parallel with common trial outcomes such as mRS.  
As more people survive stroke with long term disability1, cost-effectiveness analyses 
should take into consideration whether an intervention has longer-term benefits for stroke 
survivors. Generation of HU for various levels of dependency at longer time points post-stroke 
is desirable. Future research could also involve calculation of the adjustment factors needed to 
convert known mRS distributions to HU according to age and sex, to refine our current 
estimates. 
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Tables: 
Table 1) Baseline Demography (n=4946 participants) 
Variable Value  
Age (years); Mean (SD) 68.8 (12.6) 
Baseline NIHSS; Median (IQR) 12 (9) 
Gender (Female); n (%) 2231 (45.1%) 
RTPA (Yes); n (%) 1915 (38.7%) 
Diabetes (Yes); n (%) 1135 (22.9%) 
Hypertension (Yes); n (%) 3665 (74.1%) 
Atrial Fibrillation (Yes); n (%) 1271 (25.7%) 
Previous Stroke (Yes); n (%) 979 (19.8%) 
Transient Ischaemic Attack (Yes); n (%) 409 (8.3%) 
Myocardial Infarction (Yes); n (%) 641 (13.0%) 
Congestive heart failure (Yes); n (%) 467 (9.4%) 
 15 
 
Table 2) Mean HU derived using EQ-5D-3L, stratified by mRS (HU displayed as mean (StdDev)) and generated using available, published value sets 
Value Set applied to 
entire international 
dataset 
Modified Rankin Scale Score at 3 months  
0 (n=529) 1 (n=866) 2 (n=633) 3 (n=669) 4 (n=825) 5 (n=336) Wilcoxon Signed Rank 
Test for Differences in 
Distributions of HU, 
Relative to UK 
Distribution (p-values) 
Australia 0.93 (0.13) 0.86 (0.16) 0.76 (0.17) 0.61 (0.21) 0.35 (0.27) 0.02 (0.18) <0.0001 
China 0.92 (0.12) 0.84 (0.15) 0.73 (0.16) 0.58 (0.17) 0.37 (0.20) 0.15 (0.16) <0.0001 
Denmark 0.91 (0.15) 0.83 (0.16) 0.73 (0.16) 0.61 (0.19) 0.37 (0.19) -0.02 (0.27) <0.0001 
Germany 0.95 (0.12) 0.90 (0.14) 0.83 (0.18) 0.68 (0.23) 0.38 (0.27) 0.09 (0.18) <0.0001 
Netherlands 0.91 (0.16) 0.83 (0.18) 0.73 (0.19) 0.59 (0.23) 0.35 (0.25) 0.12 (0.21) <0.0001 
Poland 0.94 (0.11) 0.89 (0.12) 0.81 (0.14) 0.70 (0.20) 0.43 (0.29) 0.06 (0.27) <0.0001 
Singapore 0.88 (0.21) 0.74 (0.28) 0.51 (0.30) 0.23 (0.32) -0.16 (0.33) -0.48 (0.22) <0.0001 
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South Korea 0.94 (0.10) 0.88 (0.11) 0.80 (0.12) 0.69 (0.15) 0.42 (0.25) 0.09 (0.18) <0.0001 
Spain 0.93 (0.14) 0.85 (0.18) 0.72 (0.21) 0.51 (0.28) 0.09 (0.36) -0.34 (0.23) <0.0001 
UK 0.90 (0.17) 0.82 (0.19) 0.70 (0.21) 0.53 (0.26) 0.20 (0.31) -0.15 (0.23) ****** 
USA 0.92 (0.12) 0.85 (0.14) 0.77 (0.14) 0.64 (0.17) 0.41 (0.22) 0.14 (0.15) <0.0001 
Zimbabwe 0.92 (0.12) 0.85 (0.13) 0.75 (0.13) 0.63 (0.15) 0.45 (0.19) 0.22 (0.17) <0.0001 
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Table 3) Mean HU calculated using OLS Regression, stratified by mRS  
Value Set Applied 
to Analysis Dataset 
 Mean HU, by Modified Rankin Scale Score at 3 Months 
Adjusted R2 0 1 2 3 4 5 
China 68.8 0.92 0.84 0.73 0.58 0.37 0.15 
Germany 65.8 0.95 0.90 0.83 0.69 0.38 0.09 
Poland 63.7 0.94 0.89 0.81 0.70 0.44 0.07 
Spain 71.2 0.92 0.84 0.72 0.51 0.09 -0.33 
UK 65.0 0.90 0.81 0.70 0.53 0.20 -0.14 
USA 67.4 0.92 0.84 0.72 0.51 0.09 -0.33 
 18 
 
References 
 (1)  Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of 
stroke during 1990—2010: findings from the Global Burden of Disease Study 2010. 
Lancet 2014; 383, 245-254.  
 (2)  Tengs TO, Yu M, Luistro E. Health-Related Quality of Life After Stroke A 
Comprehensive Review. Stroke 2001; 32, 964-972.  
 (3)  Feeny D, Furlong W, Torrance G.W, et al. Multi-attribute and single-attribute utility 
functions for the health utilities index mark 3 system. Medical Care 2002; 40, 113-
128.  
 (4)  Hawthorne G, Richardson J, Osbourne R. The Assessment of Quality of Life (AQoL) 
instrument: A psychometric measure of health-related quality of life. Quality of Life 
Research 1999; 8, 209-224.  
 (5)  Brazier J, Rowen D. NICE DSU Technical Support Document 11:  Alternatives to 
EQ-5D for generating health state utility values. 2015; 
http://www.nicedsu.org.uk/TSD11%20Alternatives%20to%20EQ-5D_final pdf [Last 
Accessed 23/10/15]. 
 (6)  Post P, Stiggelbout AM, Wakker PP. The Utility of Health States After Stroke: A 
Systematic Review of the Literature. Stroke 2001; 32, 1425-1429.  
 (7)  Sprigg N, Selby J, Fox L, et al, Very Low Quality of Life After Acute Stroke Data 
From the Efficacy of Nitric Oxide in Stroke Trial. Stroke 2013; 44, 3458-3462.  
 (8)  Rivero-Arias O, Ouellet M, Gray A, et al. Mapping the Modified Rankin Scale (mRS) 
Measurement into the Generic EuroQol (EQ-5D) Health Outcome. Medical Decision 
Making 2010; 30, 341-354.  
 19 
 
 (9)  Whynes D, Sprigg N, Selby J, et al. Testing differential item functioning within teh 
EQ-5D. Medical Decision Making 2013; 33, 252-260.  
 (10)  Ali M, Bath P, Brady M, et al. Development, Expansion and Use of a Stroke Clinical 
Trials Resource for Novel Exploratory Analyses. International Journal of Stroke 
2012; 7, 133-138.  
 (11)  Szende A, Oppe M, Devlin NJ, Group EQ. EQ-5D Value Sets: Inventory, 
Comparative Review and User Guide. 2007; Springer.  
 (12)  Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35, 1095-
1108.  
 (13)  Shaw JW, Johnson JA, Coons SJ. US Valuation of the EQ-5D Health States: 
Development and Testing of the D1 Valuation Model.  Medical Care 2005; 43, 203-
220.  
 (14)  Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and 
Spanish general population time trade-off values for EQ-5D health states. Medical 
decision making : an international journal of the Society for Medical Decision Making 
2001; 21, 7-16.  
 (15)  Lamers LM, McDonnell J, Stalmeier PFM, et al. The Dutch tariff: results and 
arguments for an effective design for national EQ-5D valuation studies. Health 
Economics 2006; 15, 1121-1132.  
 (16)  Greiner W, Claes C, Busschbach JJ, et al. Validating the EQ-5D with time trade off 
for the German population. The European journal of health economics . HEPAC : 
health economics in prevention and care 2005; 6, 124-130.  
 (17)  Jelsma J, Hansen K, de Weerdt W, et al. How do Zimbabweans value health states?  
Population Health Metrics 2003; 1, 11.  
 20 
 
 (18)  Tsuchiya A, Ikeda S, Ikegami N, et al.  Estimating an EQ-5D population value set: the 
case of Japan. Health Econ 2002; 11, 341-353.  
 (19)  Golicki D, Jakubczyk M, Niewada M, et al. Valuation of EQ-5D health states in 
Poland: first TTO-based social value set in Central and Eastern Europe.  Value in 
health: the journal of the International Society for Pharmacoeconomics and Outcomes 
Research 2010; 13, 289-297.  
 (20)  Lee Y-K, Nam H-S, Chuang L-H.  South Korean Time Trade-Off Values for EQ-5D 
Health States: Modeling with Observed Values for 101 Health States. Value in Health 
2009; 12, 1187-1193.  
 (21)  Liu GG, Wu H, Li M, et al. Chinese Time Trade-Off Values for EQ-5D Health States. 
Value in Health 2014; 17, 597-604.  
 (22)  Luo N, Wang P, Thumboo J, et al. Valuation of EQ-5D-3L Health States in 
Singapore: Modeling of Time Trade-Off Values for 80 Empirically Observed Health 
States. Pharmacoeconomics 2014; 32, 495-507.  
 (23)  Viney R, Norman R, King MT, et al. Time Trade-Off Derived EQ-5D Weights for 
Australia. Value in Health 2011; 14, 928-936.  
 (24)  Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE 
health technology assessments. Value in health : the journal of the International 
Society for Pharmacoeconomics and Outcomes Research 2013; 16[1], 202-210.  
 (25)  Dakin H, Petrou S, Haggard M, et al. Mapping analyses to estimate health utilities 
based on responses to the OM8-30 Otitis Media Questionnaire. Quality of Life 
Research: An International Journal of Quality of Life Aspects of Treatment, Care and 
Rehabilitation 2010; 19, 65-80.  
 21 
 
 (26)  Longworth L, Rowen D. NICE DSU Technical Support Document 10: The use of 
mapping methods to estimate health state utility values. 2011; http://www 
nicedsu.org.uk [Last Accessed 23/10/15]. 
 (27)  Gold MR, Siegel JE, Russell LB. Cost effectiveness in health and medicine.  1996. 
New York, Oxford University Press.  
 (28)  Jansen SJ, Stiggelbout AM, Walker PP, et al. Unstable preferences: a shift in 
valuation or an effect of the elicitation procedure? Med Decis Making 2000; 20, 62-
71.  
 
 
